Laserable and releasable sutures preferable after trabeculectomy

Article

Laser suture lysis or releasable suture techniques can be a preferable alternative to permanent sutures for closing scleral flaps in primary trabeculectomy with mitomycin C (MMC) in uncomplicated glaucoma, according to a study published in the March issue of Journal of Glaucoma.

Laser suture lysis or releasable suture techniques can be a preferable alternative to permanent sutures for closing scleral flaps in primary trabeculectomy with mitomycin C (MMC) in uncomplicated glaucoma, according to a study published in the March issue of Journal of Glaucoma.

The study, conducted by Dr Umit Aykan and colleagues, compared the efficacy and complication rates of laser suture lysis (LSL) or releasable suture techniques after trabeculectomy. The study analysed 48 eyes of 43 patients with uncomplicated glaucoma who were recruited for primary trabeculectomy with MMC. The patients were divided into two groups of 27 and 21 eyes that were randomly assigned to a standard surgery and releasable suture groups respectively. A target intraocular pressure (IOP) was determined on the basis of the severity of the glaucoma and was called a complete success, qualified success or failure.

Group 1 recorded a mean change in IOP after LSL of 7.31±1.98 mmHg, 6.1±1.1 mmHg and 3.9±1.5 mmHg when sutures were lysed on the first, second and third months, respectively. In group 2, the mean change in IOP after releasable suture removal was 8.20±2.74 mmHg, 5.12±1.65 mmHg and 4.4±1.0 mmHg, respectively. After six months, the success rates were 92% and 90% for LSL and releasable suture groups, respectively.

The study concluded that there is an effective IOP reduction in eyes that had suture release both in the early and late postoperative periods after LSL and suture release. Both the laserable and releasable suture techniques can therefore be preferred to permanent sutures for closing scleral flaps in primary trabeculectomy with MMC in uncomplicated glaucoma.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.